These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 28453755)

  • 21. Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol.
    Gu B; De Gregorio M; Pipicella JL; Vande Casteele N; Andrews JM; Begun J; Connell W; D'Souza B; Gholamrezaei A; Hart A; Liew D; Radford-Smith G; Rimola J; Sutherland T; Toong C; Woods R; Wu Y; Xuan W; Williams AJ; Ng W; Ding NS; Connor S
    BMJ Open; 2021 Jul; 11(7):e043921. PubMed ID: 34210720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience.
    Topstad DR; Panaccione R; Heine JA; Johnson DR; MacLean AR; Buie WD
    Dis Colon Rectum; 2003 May; 46(5):577-83. PubMed ID: 12792431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease.
    Gomes LEM; da Silva FAR; Pascoal LB; Ricci RL; Nogueira G; Camargo MG; Lourdes Setsuko Ayrizono M; Fagundes JJ; Leal RF
    Clinics (Sao Paulo); 2019 Apr; 74():e824. PubMed ID: 30994711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the modified Van Assche index for assessing response to anti-TNF therapy with MRI in perianal fistulizing Crohn's disease.
    van Rijn KL; Lansdorp CA; Tielbeek JAW; Nio CY; Buskens CJ; D'Haens GRAM; Löwenberg M; Stoker J
    Clin Imaging; 2020 Feb; 59(2):179-187. PubMed ID: 31821976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy.
    Hendler SA; Cohen BL; Colombel JF; Sands BE; Mayer L; Agarwal S
    J Crohns Colitis; 2015 Mar; 9(3):266-75. PubMed ID: 25540149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of perianal fistula in Crohn's disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment.
    de Groof EJ; Sahami S; Lucas C; Ponsioen CY; Bemelman WA; Buskens CJ
    Colorectal Dis; 2016 Jul; 18(7):667-75. PubMed ID: 26921847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy.
    Papamichael K; Cheifetz AS
    World J Gastroenterol; 2017 Sep; 23(34):6197-6200. PubMed ID: 28974885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab and surgical treatment of complex anal Crohn's disease.
    Duff S; Sagar PM; Rao M; Dolling S; Sprakes M; Hamlin PJ
    Colorectal Dis; 2012 Aug; 14(8):972-6. PubMed ID: 21899707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of Infliximab on Deep Radiological Remission in Chinese Patients with Perianal Fistulizing Crohn's Disease.
    Zhu M; Xu X; Feng Q; Cui Z; Wang T; Yan Y; Ran Z
    Dig Dis Sci; 2021 May; 66(5):1658-1668. PubMed ID: 32524415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.
    Dreesen E; Van Stappen T; Ballet V; Peeters M; Compernolle G; Tops S; Van Steen K; Van Assche G; Ferrante M; Vermeire S; Gils A
    Aliment Pharmacol Ther; 2018 Feb; 47(3):346-355. PubMed ID: 29226370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction and Maintenance Infliximab Therapy for the Treatment of Crohn's Disease with Perianal Fistulas in Children: Retrospective, Multicenter Study.
    Iwańczak BM; Ryżko J; Jankowski P; Sładek M; Wasilewska A; Szczepanik M; Sienkiewicz E; Szaflarska-Popławska A; Więcek S; Kwiecień J; Korczowski B; Maślana J
    Adv Clin Exp Med; 2016; 25(3):523-30. PubMed ID: 27629741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The results of seton drainage combined with anti-TNFα therapy for anal fistula in Crohn's disease.
    Haennig A; Staumont G; Lepage B; Faure P; Alric L; Buscail L; Bournet B; Moreau J
    Colorectal Dis; 2015 Apr; 17(4):311-9. PubMed ID: 25425534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The long-term outcome of anti-TNF alpha therapy in perianal Crohn's disease.
    Rayen J; Currie T; Gearry RB; Frizelle F; Eglinton T
    Tech Coloproctol; 2017 Feb; 21(2):119-124. PubMed ID: 28066859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease.
    Oh EH; Ko DH; Seo H; Chang K; Kim GU; Song EM; Seo M; Lee HS; Hwang SW; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH
    World J Gastroenterol; 2017 Feb; 23(8):1489-1496. PubMed ID: 28293096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn's disease.
    Plevris N; Jenkinson PW; Arnott ID; Jones GR; Lees CW
    Eur J Gastroenterol Hepatol; 2020 Jan; 32(1):32-37. PubMed ID: 31567638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease.
    Roblin X; Nancey S; Papamichael K; Duru G; Flamand M; Kwiatek S; Cheifetz A; Fabien N; Barrau M; Paul S
    J Crohns Colitis; 2024 May; 18(5):679-685. PubMed ID: 37934041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
    Vermeire S; Noman M; Van Assche G; Baert F; D'Haens G; Rutgeerts P
    Gut; 2007 Sep; 56(9):1226-31. PubMed ID: 17229796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
    Cao WT; Huang R; Liu S; Fan YH; Xu MS; Xu Y; Ni H
    World J Gastroenterol; 2022 Jun; 28(23):2582-2596. PubMed ID: 35949356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.